MTOR and systemic lupus erythematosus: These results establish Rab4A as a cell type-specific controller of mitochondrial metabolism and CD98-dependent and KYN-sensitive mTOR activation that mediate therapeutically targetable pro-inflammatory lineage specification in SLE.